Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: March 3, 2001
Last updated: June 25, 2013
Last verified: October 2005